Role of Endogenous Biological Response Modifiers in Pathogenesis of Infectious Diseases

Infectious Disease Clinics of North America

Volumn 25, Issue 4, 2011, Pages 733-754

  Mullangi, Praveen K ^a   Shahani, Lokesh ^b   Koirala, Janak ^b  

^a Springfield Clinic   (United States)

^b SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Biological response modifiers; Immune response; Infection; Pathogenesis

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; BIOLOGICAL RESPONSE MODIFIER; COMPLEMENT RECEPTOR; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GLUCURONOXYLOMANNAN; INTERFERON; INTERLEUKIN 12; INTERLEUKIN 23; INTERLEUKIN DERIVATIVE; LAMBDA3 INTERFERON; PROTEINASE ACTIVATED RECEPTOR; RECOMBINANT INTERLEUKIN 2; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ACUTE LEUKEMIA; ADAPTIVE IMMUNITY; B LYMPHOCYTE ACTIVATION; BACTERIAL INFECTION; CANCER CHEMOTHERAPY; CELLULAR IMMUNITY; CHRONIC GRANULOMATOUS DISEASE; CRYPTOCOCCOSIS; DRUG EFFICACY; HELPER CELL; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNOMODULATION; IMMUNOPATHOGENESIS; INFECTION; INNATE IMMUNITY; INTERFERON PRODUCTION; KIDNEY CARCINOMA; MELANOMA; MULTIPLE SCLEROSIS; MYCOBACTERIOSIS; MYCOSIS; NONHUMAN; OSTEOPOROSIS; PARASITOSIS; PROTEIN FUNCTION; REVIEW; SEPSIS; VIRUS INFECTION;

ADAPTIVE IMMUNITY; ANTIGEN-PRESENTING CELLS; B-LYMPHOCYTES; COMMUNICABLE DISEASES; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNITY, INNATE; INTERFERONS; INTERLEUKINS; T-LYMPHOCYTES;

EID: 80455176686     PISSN: 08915520     EISSN: 15579824     Source Type: Journal    
DOI: 10.1016/j.idc.2011.07.003     Document Type: Review

References (140)

1. Tzianabos A.O. Polysaccharide immunomodulators as therapeutic agents: structural aspects and biologic function. Clin Microbiol Rev 2000, 13(4):523-533.
2. Bast R.C., Zbar B., Borsos T., et al. BCG and cancer (first of two parts). N Engl J Med 1974, 290(25):1413-1420.
3. Chang C.C., Naiki M., Halpern G.M., et al. Pharmacological regulation of the immune system. J Investig Allergol Clin Immunol 1993, 3(1):8-18.
4. Chaplin D.D. Overview of the immune response. J Allergy Clin Immunol 2010, 125(2 SUPPL 2):S3-S23.
5. Turvey S.E., Broide D.H. Innate immunity. J Allergy Clin Immunol 2010, 125(2 SUPPL 2):S24-S32.
6. Bottazzi B., Doni A., Garlanda C., et al. An integrated view of humoral innate immunity: pentraxins as a paradigm. Annu Rev Immunol 2010, 28:157-183.
7. Si-Tahar M., Touqui L., Chignard M. Innate immunity and inflammation-two facets of the same anti-infectious reaction. Clin Exp Immunol 2009, 156(2):194-198.
8. Anas A.A., Wiersinga W.J., de Vos A.F., et al. Recent insights into the pathogenesis of bacterial sepsis. Neth J Med 2010, 68(4):147-152.
9. Martinon F., Mayor A., Tschopp J. The inflammasomes: guardians of the body. Annu Rev Immunol 2009, 27:229-265.
10. Zhu J., Mohan C. Toll-like receptor signaling pathways-therapeutic opportunities. Mediators Inflamm 2010, 2010:781235.
11. Miller R.L., Meng T.C., Tomai M.A. The antiviral activity of Toll-like receptor 7 and 7/8 agonists. Drug News Perspect 2008, 21(2):69-87.
12. Commins S.P., Borish L., Steinke J.W. Immunologic messenger molecules: cytokines, interferons, and chemokines. J Allergy Clin Immunol 2010, 125(2 SUPPL 2):S53-S72.
13. Bonilla F.A., Oettgen H.C. Adaptive immunity. J Allergy Clin Immunol 2010, 125(2):S33-S40.
14. Lloyd C.M., Hessel E.M. Functions of T cells in asthma: more than just T(H)2 cells. Nat Rev Immunol 2010, 10(12):838-848.
15. Datta S., Milner J.D. Altered T-cell receptor signaling in the pathogenesis of allergic disease. J Allergy Clin Immunol 2011, 127(2):351-354.
16. Miossec P., Korn T., Kuchroo V.K. Interleukin-17 and type 17 helper T cells. N Engl J Med 2009, 361(9):888-898.
17. O'Shea J.J., Paul W.E. Mechanisms underlying lineage commitment and plasticity of helper CD4+ T cells. Science 2010, 327(5969):1098-1102.
18. Geissmann F., Manz M.G., Jung S., et al. Development of monocytes, macrophages, and dendritic cells. Science 2010, 327(5966):656-661.
19. Liu S.Y., Sanchez D.J., Cheng G. New developments in the induction and antiviral effectors of type I interferon. Curr Opin Immunol 2011, 23(1):57-64.
20. Duddy M., Haghikia A., Cocco E., et al. Managing MS in a changing treatment landscape. J Neurol 2011, 258(5):728-739.
21. Koirala J., Adamski A., Koch L., et al. Interferon-gamma receptors in HIV-1 infection. AIDS Res Hum Retroviruses 2008, 24(8):1097-1102.
22. Holland S.M. The Interferons. Cytokine therapeutics in infectious diseases 2001, 221-250. Lippincott Williams & Wilkins, Philadelphia. 1st edition. S. Holland (Ed.).
23. Segal B.H., Kwon-Chung J., Walsh T.J., et al. Immunotherapy for fungal infections. Clin Infect Dis 2006, 42(4):507-515.
24. Sternfeld T., Nigg A., Belohradsky B.H., et al. Treatment of relapsing. Mycobacterium avium infection with interferon-gamma and interleukin-2 in an HIV-negative patient with low CD4 syndrome. Int J Infect Dis 2010, 14(SUPPL 3):e198-e201.
25. Rezai M.S., Khotaei G., Mamishi S., et al. Disseminated bacillus Calmette-Guerin infection after BCG vaccination. J Trop Pediatr 2008, 54(6):413-416.
26. Seneviratne S.L., Doffinger R., Macfarlane J., et al. Disseminated Mycobacterium tuberculosis infection due to interferon gamma deficiency. Response to replacement therapy. Thorax 2007, 62(1):97-99.
27. Kedzierska K., Paukovics G., Handley A., et al. Interferon-gamma therapy activates human monocytes for enhanced phagocytosis of Mycobacterium avium complex in HIV-infected individuals. HIV Clin Trials 2004, 5(2):80-85.
28. Key L.L., Rodriguiz R.M., Willi S.M., et al. Long-term treatment of osteopetrosis with recombinant human interferon gamma. N Engl J Med 1995, 332(24):1594-1599.
29. Kelly C., Klenerman P., Barnes E. Interferon lambdas: the next cytokine storm. Gut 2011, [Epub ahead of print].
30. Miller K.D., Kuruppu J.C., Kovacs J.A. Interleukin-2. Cytokine therapeutics in infectious diseases 2001, 15-44. Lippincott Williams & Wilkins, Philadelphia. 1st edition. S. Holland (Ed.).
31. Olejniczak K., Kasprzak A. Biological properties of interleukin 2 and its role in pathogenesis of selected diseases-a review. Med Sci Monit 2008, 14(10):RA179-RA189.
32. INSIGHT-ESPRIT Study Group, SILCAAT Scientific Committee, Abrams D., Lévy Y., Losso M.H., et al. Interleukin-2 therapy in patients with HIV infection. N Engl J Med 2009, 361(16):1548-1559.
33. Penafuerte C., Bautista-Lopez N., Boulassel M.R., et al. The human ortholog of granulocyte macrophage colony-stimulating factor and interleukin-2 fusion protein induces potent ex vivo natural killer cell activation and maturation. Cancer Res 2009, 69(23):9020-9028.
34. Acres B., Gantzer M., Remy C., et al. Fusokine interleukin-2/interleukin-18, a novel potent innate and adaptive immune stimulator with decreased toxicity. Cancer Res 2005, 65(20):9536-9546.
35. Gee K., Guzzo C., Che Mat N.F., et al. The IL-12 family of cytokines in infection, inflammation and autoimmune disorders. Inflamm Allergy Drug Targets 2009, 8(1):40-52.
36. Kleinschek M.A., Muller U., Brodie S.J., et al. IL-23 enhances the inflammatory cell response in Cryptococcus neoformans infection and induces a cytokine pattern distinct from IL-12. J Immunol 2006, 176(2):1098-1106.
37. Kleinschek M.A., Müller U., Schütze N., et al. Administration of IL-23 engages innate and adaptive immune mechanisms during fungal infection. Int Immunol 2010, 22(2):81-90.
38. Parrillo J.E., Parker M.M., Natanson C., et al. Septic shock in humans. Advances in the understanding of pathogenesis, cardiovascular dysfunction, and therapy. Ann Intern Med 1990, 113(3):227-242.
39. Brown E., Atkinson J.P., Fearon D.T. Innate immunity: 50 ways to kill a microbe. Curr Opin Immunol 1994, 6(1):73-74.
40. Ezekowitz R.A., Hoffmann J.A. Innate immunity. Curr Opin Immunol 1996, 8(1):1-2.
41. Fearon D.T., Locksley R.M. The instructive role of innate immunity in the acquired immune response. Science 1996, 272(5258):50-53.
42. Oberholzer A., Oberholzer C., Moldawer L.L. Cytokine signaling-regulation of the immune response in normal and critically ill states. Crit Care Med 2000, 28(SUPPL 4):N3-N12.
43. Russell J.A. Management of sepsis. N Engl J Med 2006, 355(16):1699-1713.
44. Perianayagam M.C., Balakrishnan V.S., King A.J., et al. C5a delays apoptosis of human neutrophils by a phosphatidylinositol 3-kinasesignaling pathway. Kidney Int 2002, 61:456-463.
45. Levi M., van der Poll T. Inflammation and coagulation. Crit Care Med 2010, 38(SUPPL 2):S26-S34.
46. Petäjä J. Inflammation and coagulation. An overview. Thromb Res 2011, 127(SUPPL 2):S34-S37.
47. Kaneider N.C., Leger A.J., Agarwal A., et al. 'Role reversal' for the receptor PAR1 in sepsis-induced vascular damage. Nat Immunol 2007, 8(12):1303-1312.
48. Graves D. Cytokines that promote periodontal tissue destruction. J Periodontol 2008, 79(SUPPL 8):1585-1591.
49. Liu Y.C., Lerner U.H., Teng Y.T. Cytokine responses against periodontal infection: protective and destructive roles. Periodontol 2000, 52(1):163-206.
50. Kikkert R., Laine M.L., Aarden L.A., et al. Activation of toll-like receptors 2 and 4 by gram-negative periodontal bacteria. Oral Microbiol Immunol 2007, 22(3):145-151.
51. Nussbaum G., Ben-Adi S., Genzler T., et al. Involvement of Toll-like receptors 2 and 4 in the innate immune response to Treponema denticola and its outer sheath components. Infect Immun 2009, 77(9):3939-3947.
52. Graves D.T., Cochran D. The contribution of interleukin-1 and tumor necrosis factor to periodontal tissue destruction. J Periodontol 2003, 74(3):391-401.
53. Fonseca J.E., Santos M.J., Canhão H., et al. Interleukin-6 as a key player in systemic inflammation and joint destruction. Autoimmun Rev 2009, 8(7):538-542.
54. Garlet G.P., Martins W., Ferreira B.R., et al. Patterns of chemokines and chemokine receptors expression in different forms of human periodontal disease. J Periodontal Res 2003, 38(2):210-217.
55. Honda T., Domon H., Okui T., et al. Balance of inflammatory response in stable gingivitis and progressive periodontitis lesions. Clin Exp Immunol 2006, 144(1):35-40.
56. Amedei A., Cappon A., Codolo G., et al. The neutrophil-activating protein of Helicobacter pylori promotes Th1 immune responses. J Clin Invest 2006, 116:1092-1101.
57. Fischer W., Puls J., Buhrdorf R., et al. Systematic mutagenesis of the Helicobacter pylori cag pathogenicity island: essential genes for CagA translocation in host cells and induction of interleukin-8. Mol Microbiol 2001, 42:1337-1348.
58. Kabir S. The role of interleukin-17 in the Helicobacter pylori induced infection and immunity. Helicobacter 2011, 16(1):1-8.
59. Weel J.F., van der Hulst R.W., Gerrits Y., et al. The interrelationship between cytotoxin-associated gene A, vacuolating cytotoxin, and Helicobacter pylori-related diseases. J Infect Dis 1996, 173:1171-1175.
60. Gerber J., Nau R. Mechanisms of injury in bacterial meningitis. Curr Opin Neurol 2010, 23(3):312-318.
61. Rouse B.T., Sehrawat S. Immunity and immunopathology to viruses: what decides the outcome?. Nat Rev Immunol 2010, 10(7):514-526.
62. Iannello A., Debbeche O., Martin E., et al. Viral strategies for evading antiviral cellular immune responses of the host. J Leukoc Biol 2006, 79(1):16-35.
63. Chen J., Nag S., Vidi P.A., et al. Single molecule in vivo analysis of toll-like receptor 9 and CpG DNA interaction. PLoS One 2011, 6(4):e17991.
64. Tinoco R., Alcalde V., Yang Y., et al. Cell-intrinsic transforming growth factor-β signaling mediates virus-specific CD8+ T cell deletion and viral persistence in vivo. Immunity 2009, 31:145-157.
65. Sillanpää M., Melén K., Porkka P., et al. Hepatitis C virus core, NS3, NS4B and NS5A are the major immunogenic proteins in humoral immunity in chronic HCV infection. Virol J 2009, 6:84.
66. Nellore A., Fishman J.A. NK cells, innate immunity and hepatitis C infection after liver transplantation. Clin Infect Dis 2011, 52(3):369-377.
67. Dolganiuc A., Szabo G. Dendritic cells in hepatitis C infection: can they (help) win the battle?. J Gastroenterol 2011, 46(4):432-447.
68. Boccardo E., Lepique A.P., Villa L.L. The role of inflammation in HPV carcinogenesis. Carcinogenesis 2010, 31(11):1905-1912.
69. Balkwill F., Coussens L.M. Cancer: an inflammatory link. Nature 2004, 431(7007):405-406.
70. Kuller L.H., Tracy R., Belloso W., et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 2008, 5(10):e203.
71. Rodger A.J., Fox Z., Lundgren J.D., et al. INSIGHT Strategies for Management of Antiretroviral Therapy (SMART) Study Group. Activation and coagulation biomarkers are independent predictors of the development of opportunistic disease in patients with HIV infection. J Infect Dis 2009, 200(6):973-983.
72. Sodora D.L., Silvestri G. Immune activation and AIDS pathogenesis. AIDS 2008, 22(4):439-446.
73. Ascher M.S., Sheppard H.W. A unified hypothesis for three cardinal features of HIV immunology. J Acquir Immune Defic Syndr 1991, 4:97-98.
74. Herbeuval J.P., Hardy A.W., Boasso A., et al. Regulation of TNF-related apoptosis inducing ligand on primary CD4R T cells by HIV-1: role of type I IFN-producing plasmacytoid dendritic cells. Proc Natl Acad Sci U S A 2005, 102:13974-13979.
75. Sailaja G., Skountzou I., Quan F.S., et al. Human immunodeficiency virus-like particles activate multiple types of immune cells. Virology 2007, 362(2):331-341.
76. Brenchley J.M., Price D.A., Douek D.C. HIV disease: fallout from a mucosal catastrophe?. Nat Immunol 2006, 7:235-239.
77. Brenchley J.M., Price D.A., Schacker T.W., et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006, 12:1365-1371.
78. Nixon D.E., Landay A.L. Biomarkers of immune dysfunction in HIV. Curr Opin HIV AIDS 2010, 5(6):498-503.
79. Sandler N.G., Wand H., Roque A., et al. Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis 2011, 203(6):780-790.
80. Estaquier J., Idziorek T., de Bels F., et al. Programmed cell death and AIDS: significance of T-cell apoptosis in pathogenic and nonpathogenic primate lentiviral infections. Proc Natl Acad Sci U S A 1994, 91:9431-9435.
81. Finkel T.H., Tudor-Williams G., Banda N.K., et al. Apoptosis occurs predominantly in bystander cells and not in productively infected cells of HIV- and SIV infected lymph nodes. Nat Med 1995, 1:129-134.
82. Katsikis P.D., Wunderlich E.S., Smith C.A., et al. Fas antigen stimulation induces marked apoptosis of T lymphocytes in human immunodeficiency virus-infected individuals. J Exp Med 1995, 181:2029-2036.
83. Muro-Cacho C.A., Pantaleo G., Fauci A.S. Analysis of apoptosis in lymph nodes of HIV-infected persons. Intensity of apoptosis correlates with the general state of activation of the lymphoid tissue and not with stage of disease or viral burden. J Immunol 1995, 154:5555-5566.
84. Gougeon M.L., Lecoeur H., Dulioust A., et al. Programmed cell death in peripheral lymphocytes from HIV-infected persons: increased susceptibility to apoptosis of CD4 and CD8 T cells correlates with lymphocyte activation and with disease progression. J Immunol 1996, 156:3509-3520.
85. Badley A.D., Pilon A.A., Landay A., et al. Mechanisms of HIV-associated lymphocyte apoptosis. Blood 2000, 96:2951-2964.
86. Iannello A., Samarani S., Debbeche O., et al. Potential role of interleukin-18 in the immunopathogenesis of AIDS: involvement in fratricidal killing of NK cells. J Virol 2009, 83:5999-6010.
87. Cullen B.R., Greene W.C. Regulatory pathways governing HIV-1 replication. Cell 1989, 58:423-426. 3031.
88. de Witte L., Nabatov A., Pion M., et al. Langerin is a natural barrier to HIV-1 transmission by Langerhans cells. Nat Med 2007, 13(3):367-371.
89. de Jong M.A., de Witte L., Oudhoff M.J., et al. TNF-alpha and TLR agonists increase susceptibility to HIV-1 transmission by human Langerhans cells ex vivo. J Clin Invest 2008, 118(10):3440-3452.
90. Hammer S.M., Squires K.E., Hughes M.D., et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med 1997, 337(11):725-733.
91. Hirsch H.H., Kaufmann G., Sendi P., et al. Immune reconstitution in HIV-infected patients. Clin Infect Dis 2004, 38(8):1159-1166.
92. French M.A., Lanzo N., John M., et al. Immune restoration disease after treatment of immunodeficient HIV-infected patients with highly active antiretroviral therapy. HIV Med 2000, 1(2):107-115.
93. Shelburne S.A., Hamill R.J., Rodriguez-Barradas M.C., et al. Immune reconstitution inflammatory syndrome: emergence of a unique syndrome during highly active antiretroviral therapy. Medicine (Baltimore) 2002, 81(3):213-227.
94. Müller M., Wandel S., Colebunders R., et al. IeDEA Southern and Central Africa. Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis. Lancet Infect Dis 2010, 10(4):251-261.
95. Dhasmana D.J., Dheda K., Ravn P., et al. Immune reconstitution inflammatory syndrome in HIV-infected patients receiving antiretroviral therapy: pathogenesis, clinical manifestations and management. Drugs 2008, 68(2):191-208.
96. French M.A. Disorders of immune reconstitution in patients with HIV infection responding to antiretroviral therapy. Curr HIV/AIDS Rep 2007, 4(1):16-21.
97. Cattelan A.M., Calabro M.L., De Rossi A., et al. Long-term clinical outcome of AIDS-related Kaposi's sarcoma during highly active antiretroviral therapy. Int J Oncol 2005, 27(3):779-785.
98. Holkova B., Takeshita K., Cheng D.M., et al. Effect of highly active antiretroviral therapy on survival in patients with AIDS - associated pulmonary Kaposi's sarcoma treated with chemotherapy. J Clin Oncol 2001, 19(18):3848-3851.
99. Bower M., Nelson M., Young A.M., et al. Immune reconstitution inflammatory syndrome associated with Kaposi's sarcoma. J Clin Oncol 2005, 23(22):5224-5228.
100. Sereti I., Rodger A.J., French M.A. Biomarkers in immune reconstitution inflammatory syndrome: signals from pathogenesis. Curr Opin HIV AIDS 2010, 5(6):504-510.
101. Ruhwald M., Ravn P. Immune reconstitution syndrome in tuberculosis and HIV-co-infected patients: th1 explosion or cytokine storm?. AIDS 2007, 21(7):882-884.
102. Finke J.S., Shodell M., Shah K., et al. Dendritic cell numbers in the blood of HIV-1 infected patients before and after changes in antiretroviral therapy. J Clin Immunol 2004, 24(6):647-652.
103. Chehimi J., Campbell D.E., Azzoni L., et al. Persistent decreases in blood plasmacytoid dendritic cell number and function despite effective highly active antiretroviral therapy and increased blood myeloid dendritic cells in HIV-infected individuals. J Immunol 2002, 168(9):4796-4801.
104. Barron M.A., Blyveis N., Palmer B.E., et al. Influence of plasma viremia on defects in number and immunophenotype of blood dendritic cell subsets in human immunodeficiency virus 1 infected individuals. J Infect Dis 2003, 187(1):26-37.
105. Zelante T., Iannitti R., De Luca A., et al. IL-22 in antifungal immunity. Eur J Immunol 2011, 41(2):270-275.
106. van de Veerdonk F.L., Kullberg B.J., Netea M.G. Pathogenesis of invasive candidiasis. Curr Opin Crit Care 2010, 16(5):453-459.
107. Kaufmann S., Sher A., Ahmed R. Immunology of infectious diseases 2002, ASM Press, Washington, DC, p. 127-34.
108. Dominguez-Villar M., Hafler Immunology D.A. An innate role for IL-17. Science 2011, 332(6025):47-48.
109. Puel A., Cypowyj S., Bustamante J., et al. Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity. Science 2011, 332(6025):65-68.
110. Chai L.Y., Hsu L.Y. Recent advances in invasive pulmonary aspergillosis. Curr Opin Pulm Med 2011, 17(3):160-166.
111. Phadke A.P., Mehrad B. Cytokines in host defense against Aspergillus: recent advances. Med Mycol 2005, 43(SUPPL 1):S173-S176.
112. Stevens D.A., Moss R.B., Kurup V.P., et al. Allergic bronchopulmonary aspergillosis in cystic fibrosis-state of the art: cystic fibrosis foundation consensus conference. Clin Infect Dis 2003, 37(SUPPL 3):S225-S264.
113. Meier A., Kirschning C.J., Nikolaus T., et al. Toll-like receptor (TLR) 2 and TLR4 are essential for Aspergillus-induced activation of murine macrophages. Cell Microbiol 2003, 5:561-570.
114. Marr K.A., Balajee S.A., Hawn T.R., et al. Differential role of MyD88 in macrophage-mediated responses to opportunistic fungal pathogens. Infect Immun 2003, 71:5280-5286.
115. Zaragoza O., Rodrigues M.L., De Jesus M., et al. The capsule of the fungal pathogen Cryptococcus neoformans. Adv Appl Microbiol 2009, 68:133-216.
116. Schop J. Protective immunity against Cryptococcus neoformans infection. McGill J Med 2007, 10(1):35-43.
117. Vecchiarelli A., Retini C., Monari C., et al. Purified capsular polysaccharide of Cryptococcus neoformans induces interleukin-10 secretion by human monocytes. Infect Immun 1996, 64(7):2846-2849.
118. Deepe G.S., Seder R.A. Molecular and cellular determinants of immunity to Histoplasma capsulatum. Res Immunol 1998, 149:397-406.
119. Rappleye C.A., Eissenberg L.G., Goldman W.E. Histoplasma capsulatum alpha-(1,3)-glucan blocks innate immune recognition by the beta-glucan receptor. Proc Natl Acad Sci U S A 2007, 104(4):1366-1370.
120. Gorocica P., Taylor M.L., Alvarado-Vásquez N., et al. The interaction between Histoplasma capsulatum cell wall carbohydrates and host components: relevance in the immunomodulatory role of histoplasmosis. Mem Inst Oswaldo Cruz 2009, 104(3):492-496.
121. Volkman H.E., Pozos T.C., Zheng J., et al. Tuberculous granuloma induction via interaction of a bacterial secreted protein with host epithelium. Science 2010, 327(5964):466-469.
122. Agarwal N., Bishai Microbiology W.R. Subversion from the sidelines. Science 2010, 327(5964):417-418.
123. Mishra B.B., Moura-Alves P., Sonawane A., et al. Mycobacterium tuberculosis protein ESAT-6 is a potent activator of the NLRP3/ASC inflammasome. Cell Microbiol 2010, 12(8):1046-1063.
124. Khader S.A., Cooper A.M. IL-23 and IL-17 in tuberculosis. Cytokine 2008, 41(2):79-83.
125. Jacobson M.A., Spritzler J., Landay A., et al. A phase I, placebo-controlled trial of multi-dose recombinant human interleukin-12 in patients with HIV infection. AIDS 2002, 16(8):1147-1154.
126. Greinert U., Ernst M., Schlaak M., et al. Interleukin-12 as successful adjuvant in tuberculosis treatment. Eur Respir J 2001, 17(5):1049-1051.
127. Mendez-Samperio Expression and regulation of chemokines in mycobacterial infection. J Infect 2008, 57(5):374-384.
128. Jackson J.A., Friberg I.M., Little S., et al. Review series on helminths, immune modulation and the hygiene hypothesis: immunity against helminths and immunological phenomena in modern human populations: coevolutionary legacies?. Immunology 2009, 126(1):18-27. [review erratum in: Immunology 2009 Mar;126(3):446].
129. Coffman R.L. Immunology. The origin of TH2 responses. Science 2010, 328(5982):1116-1117.
130. Carvalho L., Sun J., Kane C., et al. Review series on helminths, immune modulation and the hygiene hypothesis: mechanisms underlying helminth modulation of dendritic cell function. Immunology 2009, 126(1):28-34.
131. Moreau E., Chauvin A. Immunity against helminths: interactions with the host and the intercurrent infections. J Biomed Biotechnol 2010, 2010:428593.
132. Murdoch C., Finn A. Chemokine receptors and their role in inflammation and infectious diseases. Blood 2000, 95(10):3032-3043. [review].
133. Maestre A., Muskus C., Duque V., et al. Acquired antibody responses against Plasmodium vivax infection vary with host genotype for Duffy antigen receptor for chemokines (DARC). PLoS One 2010, 5(7):e11437.
134. Ercolini A.M., Miller S.D. The role of infections in autoimmune disease. Clin Exp Immunol 2009, 155(1):1-15.
135. Wucherpfennig K.W. Mechanisms for the induction of autoimmunity by infectious agents. J Clin Invest 2001, 108(8):1097-1104.
136. Dale J.B., Beachey E.H. Epitopes of streptococcal M proteins shared with cardiac myosin. J Exp Med 1985, 162:583-591.
137. Neisser A., Schwerer B., Bernheimer H., et al. Ganglioside-induced antiganglioside antibodies from a neuropathy patient cross-react with lipopolysaccharides of Campylobacter jejuni associated with Guillain-Barre syndrome. J Neuroimmunol 2000, 102:85-88.
138. Stetson D.B. Connections between antiviral defense and autoimmunity. Curr Opin Immunol 2009, 21(3):244-250.
139. Bouley D.M., Kanangat S., Wire W., et al. Characterization of herpes simplex virus type-1 infection and herpetic stromal keratitis development in IFN-gamma knockout mice. J Immunol 1995, 155:3964-3971.
140. Elkind M.S. Impact of innate inflammation in population studies. Ann N Y Acad Sci 2010, 1207:97-106.